Back to Safety & Best Practices
Safety & Best Practices•••14 min read

CBL-514: What the Investigational Fat-Reduction Injection Is (Not a Peptide)

CBL-514 is Caliway's investigational small-molecule fat-reduction injection in Phase 3 — not a peptide, not FDA-approved. Mechanism, trial data, Kybella comparison, and GLP-1 combo studies.

PeptIQ Team
Peptide Research & Education
CBL-514: What We Know About the Fat-Reduction Injection in Phase 3 (and Why It's Not a Peptide)

PeptIQ app

Track your peptide protocols in PeptIQ

Log injections, vial supply, and reminders. Use peptiq.io calculators when you need math on the web.

Get the appOpen web app

iOS, Android, and web

Research supplier

Tirzepatide listings are for laboratory / research use only — not for human consumption.

Research use only. Partner link. PeptIQ may earn a referral fee. Not medical advice.

Ask PeptIQ

Two taps on our guided quiz, then keep going in iMessage with sources — not Instagram screenshots.

Start the quizOr try Peptide X Quiz →

Under 25? Talk to a licensed clinician and get baseline labs before starting anything. Why we say this · Labs checklist

TL;DR

CBL-514 is not a peptide. It is a patented small-molecule injectable developed by Caliway Biopharmaceuticals (TWSE: 6919) on a 505(b)(1) new drug path. It is designed to reduce localized subcutaneous fat by selectively pushing adipocytes into apoptosis, shrinking fat-cell number in treated areas rather than only shrinking existing cells.

It is investigational and not FDA-approved. The company is running two global pivotal Phase 3 trials (SUPREME-01 and SUPREME-02). Anything sold online as "CBL-514" is not the Caliway study drug.

If you landed here after searching "CBL-514 peptide," this page exists to correct that framing and point to verified sources. PeptIQ.io is education only: no dosing advice, no vendor links, no treatment recommendations.

Is CBL-514 a peptide?

No. Peptides are chains of amino acids. CBL-514 is described repeatedly in Caliway disclosures and peer-reviewed aesthetic medicine papers as a small-molecule injection, not a peptide hormone, not a GLP-1 analog, and not a growth-hormone fragment.

Retail sites that list "CBL-514 peptide" are mislabeled. They are not selling an FDA-reviewed version of Caliway's compound. Do not interpret catalog names as access to clinical trial material.

For the full compound profile (mechanism, trials, FAQs), see CBL-514 on PeptIQ.

What CBL-514 is supposed to do

Caliway's public description: CBL-514 selectively induces adipocyte apoptosis to reduce subcutaneous fat at the injection site, aiming to avoid necrosis or damage to surrounding tissue. That is a different story from:

  • Whole-body weight-loss drugs (semaglutide, tirzepatide, retatrutide) that act on appetite and incretin receptors.
  • Kybella (deoxycholic acid), the only FDA-approved injectable for localized fat reduction, limited to submental (under-chin) fat.

CBL-514 targets large-area abdominal subcutaneous fat in its Phase 3 program — a contouring indication Kybella is not approved to treat.

How it differs from Kybella (deoxycholic acid)

CBL-514Kybella (deoxycholic acid)
Molecule classSmall molecule (investigational)Small molecule (approved)
Mechanism (as described)Adipocyte apoptosisDisrupts adipocyte membranes in treated tissue
U.S. regulatory statusNot FDA-approved; Phase 3FDA-approved for submental fat only
Typical study areaAbdominal subcutaneous fat (trials)Submental fat (label)
NDA pathway (Caliway)Intended 505(b)(1)Approved NDA

Caliway's April 2026 investor materials compared Phase 2b two-grade responder rates (21.2% on active drug vs 0% placebo in one analysis set) to historical Kybella pivotal figures (about 13.4%–18.6% in cited comparators). Those figures come from different indications and trial designs; they are not a head-to-head trial.

Human evidence so far (published and presented)

Phase 2a (abdominal fat)

A 2022 Aesthetic Surgery Journal phase IIa paper reported early human work on targeted adipocyte apoptosis with CBL-514 injections.

Phase 2 (abdominal subcutaneous fat)

A 2025 randomized phase II trial (same report at PubMed PMID 40037659) in Aesthetic Surgery Journal found that 69.6% of CBL-514-treated participants met a prespecified ≥150 mL subcutaneous fat volume loss threshold at 8 weeks after the final treatment vs 0% on placebo (P < .001) in the intention-to-treat set. Injection-site reactions were the most common adverse events and were mostly mild to moderate.

Phase 2b (patient + clinician scales)

A 2026 phase 2b publication added clinician- and patient-reported abdominal fat rating scales plus MRI. Caliway's August 2026 investor conference cited completed study CBL-0205: in the full analysis set, 21.2% of treated participants achieved ≥2-grade improvement on combined physician and patient scales vs 0% placebo (p<0.005), and 63.6% achieved ≥1-grade improvement vs 10.8% placebo (p<0.0001).

Visceral fat subgroup (EASD 2026)

News coverage of Caliway's EASD presentation (News-Medical, Oct 2026; Science News, Oct 2026) described an MRI analysis in a subgroup of phase 2 participants with available scans. Reported patterns included VAT decreases in the active group and increases on placebo at follow-up, with between-group differences on the order of ~17–22% depending on timepoint. Subgroup sizes were small; this is exploratory, not a labeled claim.

Dercum's disease (CBL-514D)

Caliway develops a related formulation CBL-514D for Dercum's disease. A 2026 phase 2a paper studied lipomas in Dercum's disease. The company's September 2026 release said study CBL-0202DD met its pain primary endpoint vs placebo and that topline work continued in related conditions (e.g. lipedema research interest). None of this is an approved Dercum's treatment.

Phase 3: SUPREME program

After FDA discussions, Caliway aligned SUPREME-01 (NCT07140939) on a co-primary endpoint: proportion of participants with ≥2-grade improvement on both PR-AFRS and CR-AFRS scales, with MRI abdominal subcutaneous fat volume as a key secondary endpoint. The trial targets ~320 adults (BMI roughly 18.5–30) across the U.S. and Canada, with up to four monthly treatment courses and substantial injection volume per session in the protocol (study-specific).

SUPREME-02 (NCT07526974) is the parallel pivotal study (~320 subjects; U.S., Canada, Australia). Caliway submitted a U.S. IND for SUPREME-02 in April 2026. As of registry metadata in late 2026, SUPREME-01 was recruiting with first participant dosed in September 2026 (company release).

What we do not know yet: final Phase 3 efficacy, durability years out, visceral-fat claims on a label, combination use with GLP-1 drugs in routine care, pricing, or who (if anyone) will be eligible on an approved label.

Tirzepatide combination and weight regain (still investigational)

Whole-body GLP-1 medicines remain the backbone of pharmacologic obesity treatment. Weight regain after stopping GLP-1s is a documented problem in withdrawal trials — a different problem from pinchable abdominal contour.

Caliway reports preclinical work combining CBL-514 with tirzepatide or semaglutide, with additive fat loss and less weight rebound after stopping the GLP-1 in animal models (figures such as ~46% vs ~17% rebound appeared in August 2026 investor materials). Those are not human combination guidelines.

A Phase 2 combination study CBL-0201WR (CBL-514 + tirzepatide, ~120 subjects, 10 U.S. sites) received FDA IND clearance in August 2026, per the same investor update. Primary endpoint framing in that disclosure centers on MRI subcutaneous abdominal fat after treatment discontinuation, with weight and visceral fat as exploratory measures.

That path might interest people stacking tirzepatide with contouring tools — but only trials can answer safety and benefit. PeptIQ does not endorse off-label stacking.

Safety signals reported to date

Across published phase 2 work, injection-site reactions (pain, swelling, redness) dominate tolerability discussions. Company summaries emphasize lack of serious treatment-emergent events in those datasets. Phase 3 will define the safety database regulators review.

CBL-514 is not available for self-administration outside trials. It is not a lyophilized "peptide vial" reconstitution product.

What is not known (and what to ignore online)

  • No approved dose, no home-use kit, no compounding pathway for Caliway's drug.
  • No proof that preclinical GLP-1 combo or regain data will replicate in people at scale.
  • Visceral-fat and metabolic benefit remain hypotheses pending larger, controlled programs.
  • Vendor listings using the name CBL-514 are unverified and unrelated to the investigational NDA candidate.

For contrast with peptide and small-molecule research compounds people confuse with obesity drugs, see peptides for weight loss, AOD-9604, MOTS-c, tesamorelin (HIV lipodystrophy only), and 5-Amino-1MQ.

How PeptIQ.io helps

Use the PeptIQ download page to track approved medicines you already use with a clinician — doses, check-ins, and weight trends on one timeline. CBL-514 belongs in the watch the literature bucket until regulators and peer-reviewed phase 3 reports exist.

Clinics exploring body-composition programs can use PeptIQ for patient education and adherence without turning guides into product claims.

This article is educational content from PeptIQ.io. It is not medical advice. Talk with a licensed clinician before starting, stopping, or changing any peptide, medication, or injection practice.

Frequently Asked Questions

Q: Is CBL-514 a peptide?

A: No. Caliway and published clinical papers describe it as a small-molecule injectable. Online "peptide" labels are incorrect marketing.

Q: Is CBL-514 FDA-approved?

A: No. It is investigational. Kybella remains the only FDA-approved injectable for localized fat reduction (submental only).

Q: Can I buy CBL-514 for research?

A: PeptIQ does not sell compounds or link vendors. Listings sold as CBL-514 are not Caliway's investigational product and have not passed FDA NDA review.

Q: How is CBL-514 different from semaglutide or tirzepatide?

A: GLP-1 drugs reduce appetite and body weight systemically. CBL-514 is studied as a local adipocyte-reduction injection for abdominal contour, with separate combination trials in development.

Q: Does CBL-514 reduce visceral fat?

A: Early MRI substudies and EASD 2026 presentations reported VAT changes in small subgroups. That is not an approved indication or a clinical recommendation.

Q: When will Phase 3 results be available?

A: Registry dates for SUPREME-01/02 point to primary completion around 2027. Company timelines can change.

Related guides

Selected sources

For clinics: running peptide or GLP-1 programs for patients? See PeptIQ.io for providers: protocol templates, a patient app, and adherence tracking in one console.

Share this article

Track Your Peptide Protocols

Use PeptIQ to log injections and vial supply, use peptiq.io calculators for math on the web, and keep protocols organized.

Stay ahead of the peptide conversation

Weekly-ish notes on new research, wiki trends, and practical tracking tips. No spam — unsubscribe anytime.

Educational updates only — not medical advice. Privacy